Infection · Moderate
This case is fictional and exists for study. It describes no real patient.
68 years · female
A 68-year-old female is reviewed on the medical ward 48 hours after admission for community-acquired pneumonia. On admission, she presented with fever, cough, and dyspnoea, with a CURB-65 score of 2. She was started on intravenous co-amoxiclav and oral clarithromycin. Today, she reports feeling significantly better, her cough is producing less sputum, and she is eating and drinking well. Vital signs show resolution of her fever and normalisation of respiratory parameters. Sputum culture collected on admission has grown Streptococcus pneumoniae, which is fully sensitive to penicillin. Blood cultures show no growth to date.
Vital signs
- HR
- 72 bpm
- BP
- 124/78 mmHg
- RR
- 16/min
- Temp
- 36.8 °C
- SpO₂
- 97%
Examination findings
- Mild residual bronchial breath sounds at the right base
- No respiratory distress
- Intravenous cannula site in left forearm is clean with no erythema
Investigations
| White blood cell count | 7.2 10^9/L | reference: 4.0-11.0 |
| C-reactive protein (CRP) | 28 mg/L | reference: <5 |
Question 1 of 3
Which of the following is the most appropriate next step in this patient's antibiotic management?
The patient meets all criteria for IV-to-oral switch (clinically improving, afebrile for >24 hours, normal vitals, tolerating oral fluids/food). Furthermore, microbiological results show Streptococcus pneumoniae sensitive to penicillin. Antibiotic stewardship principles dictate de-escalation from broad-spectrum empirical coverage (co-amoxiclav + clarithromycin) to narrow-spectrum targeted therapy (oral amoxicillin). Continuing IV therapy unnecessarily increases catheter-related complications. Continuing dual broad-spectrum therapy increases the risk of side effects, Clostridioides difficile infection, and antimicrobial resistance. Discontinuing antibiotics completely is premature as she has not completed an adequate duration of treatment for pneumonia.
Teaching point: Antimicrobial stewardship requires de-escalating to narrow-spectrum oral targeted therapy once sensitivity results are available and the patient is clinically improving.
Question 2 of 3
The patient asks why her intravenous antibiotics are being stopped. Which explanation best reflects the core principles of antimicrobial stewardship?
Timely switching from IV to targeted oral therapy reduces line-associated risks (e.g., phlebitis, bloodstream infections), shortens hospital stay, and minimizes selective pressure for antibiotic resistance, without compromising clinical cure rates. Option B is false; IV antibiotics do not lose efficacy over time. Option D is incorrect because IV antibiotics are indicated for severe infection/sepsis or malabsorption, not solely swallow inability. Option A is incorrect as duration of IV administration does not inherently increase immediate allergic reaction risk.
Teaching point: Timely IV-to-oral switch reduces catheter-related complications and antimicrobial resistance without compromising clinical outcomes.
Question 3 of 3
Which finding in this patient provides the strongest justification for narrowing her antibiotic spectrum (de-escalation)?
De-escalation (narrowing the spectrum of activity) relies on microbiological confirmation of a specific pathogen and its drug sensitivities. Identifying penicillin-sensitive Streptococcus pneumoniae allows targeted coverage with amoxicillin rather than broad-spectrum agents. Normal WBC count and fever resolution (options A and B) support the decision to switch from IV to oral route due to clinical stability, but do not dictate which specific agent to select. Negative blood cultures (option D) rule out bacteraemia but do not specify the causative pathogen in the lung.
Teaching point: De-escalation from broad-spectrum to narrow-spectrum antibiotic therapy is driven by definitive microbiological culture and sensitivity data.
Key learning points
- Patients on empirical broad-spectrum antibiotics should be reassessed at 48-72 hours for IV-to-oral switch and de-escalation based on culture results.
- Key criteria for IV-to-oral switch include clinical improvement, afebrile status for >24 hours, vital sign stability, and intact gastrointestinal absorption.
- De-escalating to narrow-spectrum therapy (e.g., amoxicillin for penicillin-sensitive S. pneumoniae) minimizes the risk of Clostridioides difficile infection and selective resistance.
This is one of 158 free cases
AskPreceptor is a study tool for medical students: answer first, then see the reasoning — including why each wrong option is wrong. Free, no sign-up required.